The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
about
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentElevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer CellsProgrammed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptorImmunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.PD-1/PD-L1 blockage in cancer treatment-from basic research to clinical application.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.HIV-Associated Lung Cancer.Radiotherapy and immunotherapy: a beneficial liaison?Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.Inflammatory microenvironment in the initiation and progression of bladder cancer.Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.Role of immune microenvironment in gastrointestinal stromal tumours.The emerging role of immune checkpoint based approaches in AML and MDS.Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
P2860
Q26740288-3B08F5BF-3EA5-4E14-A7A8-4A88694197DCQ27853353-47295F62-3A7A-49DF-8B19-7B2542168684Q28076071-C000FDF3-0B08-43F8-A6B3-44AEE9D7BE33Q28076294-F3337087-1AE0-44AE-8B4A-DCE16905A5A9Q37303319-761918BC-32AB-4084-A4D6-8094F500BFA0Q37322466-F866EAB8-0D7F-4C7A-ABB2-68C771C2D311Q37327597-AC50F7EB-D809-4541-8445-268564F6BF2DQ37564425-2EC596FD-CAAB-4F20-8121-7AA9FF7F0707Q37662169-2D40F28F-5FE7-4D71-841F-C127805C199DQ37725613-E7563973-30A6-46B8-83B8-5C59A908F8C1Q38770455-48E97F6B-BEAC-4C39-B0EF-F4A205845580Q38770458-10EB582D-677F-4D54-BCB2-C263CA41D7D2Q38929261-EAC352A2-B72B-4F6E-9C45-DB3FF9227E52Q39017268-216E969F-48A9-4BA2-8AB3-513C879EDB78Q39193035-113517B3-16A0-4FFA-A7FA-2E55541E727CQ40117779-34D885F3-6003-4384-B9F2-F986B7CF1B81Q41221347-E1EB50C2-6A0D-4F99-9D0E-D88C41972EC8Q41709168-297A2D47-B3B5-4BF7-97A6-6F64E7553C3DQ46779353-47FBD74E-3945-4218-8700-647EB819912CQ47112946-BB9552E1-6949-4074-9667-5E31293EFF7BQ47856440-D1018C07-94A1-46B8-9EEE-A6D5C87F6460Q48173100-8020DE71-B54B-4ACA-8B16-763B618636CDQ55263819-FA512005-52BD-43AC-B5C4-B5486C925241
P2860
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The anticancer immune response ...... antibodies in cancer patients
@ast
The anticancer immune response ...... antibodies in cancer patients
@en
The anticancer immune response ...... antibodies in cancer patients
@nl
type
label
The anticancer immune response ...... antibodies in cancer patients
@ast
The anticancer immune response ...... antibodies in cancer patients
@en
The anticancer immune response ...... antibodies in cancer patients
@nl
prefLabel
The anticancer immune response ...... antibodies in cancer patients
@ast
The anticancer immune response ...... antibodies in cancer patients
@en
The anticancer immune response ...... antibodies in cancer patients
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
The anticancer immune response ...... antibodies in cancer patients
@en
P2093
Hongming Pan
Junhong Ma
Weidong Han
Xinbing Sui
P2860
P304
P3181
P356
10.18632/ONCOTARGET.5107
P407
P5008
P577
2015-08-14T00:00:00Z